Certara (NASDAQ:CERT) Reaches New 12-Month Low – Time to Sell?

Certara, Inc. (NASDAQ:CERT) shares hit a new 52-week low on Monday . The company traded as low as $5.63 and last traded at $5.6240, with a volume of 4361473 shares changing hands. The stock had previously closed at $5.75.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Leerink Partners reiterated an “outperform” rating and set a $10.00 target price on shares of Certara in a research note on Thursday, February 26th. Morgan Stanley cut their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Finally, Stephens dropped their price objective on Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Certara presently has an average rating of “Hold” and an average target price of $11.10.

Certara Stock Performance

The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The firm has a 50-day simple moving average of $7.35 and a 200 day simple moving average of $9.29. The company has a market cap of $903.92 million, a price-to-earnings ratio of -568.00 and a beta of 1.50.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. Certara’s revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.15 earnings per share. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, sell-side analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CERT. Associated Banc Corp increased its stake in Certara by 9.7% in the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after purchasing an additional 1,051 shares during the period. Versant Capital Management Inc boosted its stake in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after buying an additional 1,153 shares during the period. Osaic Holdings Inc. grew its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares during the last quarter. Corient Private Wealth LLC grew its holdings in shares of Certara by 11.1% during the second quarter. Corient Private Wealth LLC now owns 12,299 shares of the company’s stock worth $144,000 after buying an additional 1,232 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its position in Certara by 2.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock valued at $663,000 after acquiring an additional 1,597 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.